Senstend Den Europæiske Union - dansk - EMA (European Medicines Agency)

senstend

plethora pharma solutions limited - lidocain, prilocaine - for tidlig sædafgang - anæstesiologi - senstend er indiceret til behandling af primær tidlig sædafgang hos voksne mænd.

Sutent Den Europæiske Union - dansk - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Galieve Cool Mint 500+267+160 mg/10 ml oral suspension Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

galieve cool mint 500+267+160 mg/10 ml oral suspension

reckitt benckiser healthcare (scandinavia) a/s - calciumcarbonat, natriumalginat, natriumhydrogencarbonat - oral suspension - 500+267+160 mg/10 ml

Galieve Cool Mint 500+267+160 mg/10 ml oral suspension i brev Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

galieve cool mint 500+267+160 mg/10 ml oral suspension i brev

reckitt benckiser healthcare (scandinavia) a/s - calciumcarbonat, natriumalginat, natriumhydrogencarbonat - oral suspension i brev - 500+267+160 mg/10 ml

Galieve Forte 500+213+325 mg/10 ml oral suspension i brev Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

galieve forte 500+213+325 mg/10 ml oral suspension i brev

reckitt benckiser a/s - calciumcarbonat, natriumalginat, natriumhydrogencarbonat - oral suspension i brev - 500+213+325 mg/10 ml